Table 1 |.
Examples of therapeutics targeting leukaemia engagement with the metastatic niche
| Target | Type | Therapy | Condition | Clinical trial number | Phase | Status | Refs |
|---|---|---|---|---|---|---|---|
| CXCR4 | Small molecule | AMD3100 + MEC | R/R AML | NCT00512252 | I/II | Completed | 198 |
| CXCR4 | Small molecule | AMD3100 + G-CSF (filgastrim) | R/R AML | NCT00906945 | I/II | Completed | 199 |
| CXCR4 | Small molecule | BL-8040 + AraC | R/R AML | NCT01838395 | II | Completed | 227 |
| CXCR4 | Small molecule | Dociparstat + chemotherapy | AML | NCT04571645 | III | Not yet recruiting | 206,208,209 |
| CXCR4 | Small molecule | BL-8040 + nelarabine | R/R T-ALL | NCT02763384 | II | Recruiting | 228 |
| CCR7 | Monoclonal antibody | CAP-100 | R/R CLL | NCT04704323 | I | Not yet recruiting | 159,210 |
| CCR7 | Antibody–drug conjugate | JBH492 | CLL + NHL | NCT04240704 | I | Recruiting | 211 |
| CCR4 | Monoclonal antibody | Mogamulizumab | R/R ATLL | NCT04185220 | I | Active, not recruiting | 213 |
| G-CSF | Recombinant protein | Recombinant G-CSF (filgastrim) + chemotherapy | AML | #NTR230 | III | Completed | 203 |
| E-selectin | Small molecule | GMI-1271 + chemotherapy | R/R AML | NCT03616470 | III | Recruiting | 214 |
| BTK | Small molecule | Ibrutinib | CLL | NCT02048813 | III | Active | 58 |
| PI3Kδ | Small molecule | Idelalisib | CLL | NCT01539512 | III | Completed | 229 |
| PI3Kα/δ/γ | Small molecule | Copanlisib | R/R B-ALL | NCT04803123 | Window of opportunity | Active, not recruiting | 225 |
ALL, acute lymphocytic leukaemia/lymphoma; AML, acute myeloid leukaemia; AraC, cytarabine; ATLL, adult T cell leukaemia/lymphoma; B-ALL, B cell ALL; BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukaemia; G-CSF, granulocyte colony-stimulating factor; MEC, mitoxantrone, etoposide and cytarabine; NHL, non-Hodgkin lymphoma; R/R, relapsed/refractory; T-ALL, T cell ALL.